AL003 targets a sialic acid binding Ig-like lectin 3 (SIGLEC 3) that
is genetically linked to Alzheimer’s disease.
AL003 is being developed by Alector for the treatment of Alzheimer’s disease and Alector is responsible for the execution of Phase 1 and Phase 2 studies. Following its exercise of an option for a program, AbbVie will be responsible for certain development activities and global commercialization.
Type of MoleculeBiologic
Product TypeNew Indication
|Potential Indication||Region||Phase (1, 2, 3, Submitted)|
|Alzheimer's Disease (AD)||n/a||